8-K: Sagimet Biosciences Reports Positive Acne Trial Data, Terminates ATM Offering

Sagimet Biosciences announced positive 52-week results from a Phase 3 open-label extension trial for denifanstat in acne and terminated its At-the-Market offering.

Summary

• Sagimet Biosciences has announced positive 52-week results from the Phase 3 ASC40-304 open-label extension (OLE) clinical trial of denifanstat for moderate to severe acne vulgaris, conducted by its license partner Ascletis in China.
• The OLE trial showed progressive and sustained improvements in efficacy endpoints, including Investigator's Global Assessment (IGA) success (57% response rate), a 72% reduction in total lesions, and a 77% reduction in inflammatory lesions.
• Denifanstat was generally well-tolerated throughout the 52-week treatment period, with no adverse event-related permanent discontinuations.
• The company also announced the termination of its At-the-Market (ATM) Prospectus Supplement related to its Series A common stock, effective September 30, 2026.
• Patient screening for the U.S. AURORA Phase 3 clinical trial for denifanstat in acne is expected to begin in October 2026.
• Sagimet is also advancing its other FASN inhibitor, TVB-3567, with a Phase 1 clinical trial initiated in June 2025, and plans to initiate a Phase 2 trial by the end of 2026.
• Development for MASH (metabolic dysfunction-associated steatohepatitis) is contingent on securing non-dilutive funding.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a positive development, with strong clinical trial results and a clear path forward for denifanstat in acne treatment, alongside progress in other indications.

Positives

• Positive 52-week results from the Phase 3 ASC40-304 open-label extension trial of denifanstat in moderate to severe acne vulgaris, showing sustained improvements in IGA success, total lesion count, and inflammatory lesion count.
• Denifanstat demonstrated a 57% treatment success rate, a 72% reduction in total lesions, and a 77% reduction in inflammatory lesions in the OLE trial.
• Denifanstat was generally well-tolerated over 52 weeks with no adverse event-related permanent discontinuations and no drug-related serious adverse events.
• The U.S. AURORA Phase 3 clinical trial for denifanstat in acne is on track to initiate patient screening in October 2026.
• The company's follow-on FASN inhibitor, TVB-3567, has initiated Phase 1 clinical trials, with Phase 2 planned for late 2026.
• The company reported $257.6 million in cash as of June 30, 2026, expected to fund operations through 2028.
• Denifanstat met all primary and secondary endpoints in the Phase 3 ASC40-303 trial in China, and its NDA was accepted by the China NMPA in December 2025.

Negatives

• Further development for MASH is contingent upon securing non-dilutive funding, indicating a potential hurdle for advancing this indication.
• The termination of the At-the-Market (ATM) Prospectus Supplement means no further sales of common stock will occur under that agreement unless a new filing is made, potentially impacting short-term capital flexibility.

Risks

• The clinical development and therapeutic potential of denifanstat, TVB-3567, or any other drug candidates.
• The ability to advance drug candidates into and successfully complete clinical trials within anticipated timelines.
• Unfavorable new clinical trial data may emerge in other clinical trials of product candidates.
• Clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities.
• The relationship with Ascletis and the success of its development efforts for denifanstat.
• The accuracy of estimates regarding capital requirements.
• The ability to maintain and successfully enforce adequate intellectual property protection.
• New risk factors and uncertainties may emerge from time to time in the dynamic biopharmaceutical industry.

Future Outlook

Sagimet plans to advance denifanstat into a Phase 3 clinical trial in the US for moderate to severe acne in the second half of 2026. The company also plans to initiate a Phase 2 clinical trial for TVB-3567 in acne before the end of 2026, subject to regulatory consultation and Phase 1 results. Further MASH development is contingent on securing non-dilutive funding.

Management Comments

• "The positive results presented today at EADV reinforce our confidence in denifanstat as we prepare to begin patient screening for our U.S. AURORA Phase 3 clinical trial in October, with first patient enrollment expected shortly thereafter," said David Happel, Chief Executive Officer of Sagimet.
• "The open-label extension trial provides important data to support our AURORA Phase 3 program," said Andreas Grauer, MD, Chief Medical Officer of Sagimet. "It is particularly encouraging that patients continued to improve with longer treatment, and denifanstat remained generally well-tolerated through the open-label extension trial, with exposure to denifanstat up to 52 weeks. Notably, patients who crossed over from placebo achieved treatment success rates similar to those treated with denifanstat from the start. Together, these results provide meaningful long-term experience with the 50 mg denifanstat dose we are taking forward in AURORA."

Industry Context

StockSavvy.ai notes that the positive results for denifanstat in acne align with the growing market for acne treatments and the ongoing search for novel mechanisms of action, particularly oral therapies, given the chronic nature of the condition for many patients.

Comparison to Industry Standards

• The Phase 3 ASC40-303 trial in China met all primary and secondary endpoints, demonstrating statistically significant improvements in IGA success and lesion counts compared to placebo, which is a standard benchmark for acne treatments.
• The OLE trial results showing sustained efficacy and good tolerability over 52 weeks provide long-term data that is crucial for regulatory submissions and market positioning, exceeding the typical 12-week primary endpoint duration of many acne trials.
• The planned U.S. AURORA Phase 3 trial with approximately 800 patients, including a significant adolescent cohort (450 patients aged 12-17), follows industry standards for pivotal trials in this indication.
• The development of TVB-3567, a follow-on FASN inhibitor, mirrors industry strategies of having multiple candidates in development to address potential future needs or competitive landscapes.

Stakeholder Impact

• Shareholders: Positive clinical data and progress in development pipelines may lead to increased investor confidence. Termination of ATM offering might affect short-term capital raising flexibility.
• Patients with moderate to severe acne: Potential for a new, well-tolerated, once-daily oral treatment option with a novel mechanism of action if denifanstat is approved.
• License partner Ascletis: Successful trial results in China support their development and commercialization efforts for denifanstat.
• Creditors/Suppliers: Continued operations through 2028 based on current cash position suggest stability in meeting financial obligations.

Next Steps

• Initiate patient screening for the U.S. AURORA Phase 3 clinical trial for denifanstat in acne in October 2026.
• Complete all development and regulatory activities for denifanstat-resmetirom combination Phase 2 readiness by the end of 2026.
• Consult with regulatory authorities regarding Phase 2 clinical trial design for TVB-3567, with the goal of initiating the trial before the end of 2026.

Key Dates

Recommendation

The positive clinical data for denifanstat in acne is encouraging, and the company has a solid cash position. However, the reliance on non-dilutive funding for MASH development and the ongoing nature of Phase 3 trials in the US warrant a 'hold' recommendation until further de-risking events occur, such as successful completion of the AURORA trial and regulatory submissions.

Keywords

denifanstat, acne vulgaris, FASN inhibitor, clinical trial, ASC40-304, ASC40-303, Ascletis, AURORA trial